Centene Extends SilverSummit's Presence to the Edges of Nevada

11.04.25 17:46 Uhr

Werte in diesem Artikel
Aktien

53,90 EUR -0,55 EUR -1,01%

Indizes

5.525,2 PKT 40,4 PKT 0,74%

935,5 PKT -8,9 PKT -0,94%

Centene Corporation CNC recently announced that its subsidiary, SilverSummit Healthplan, has received a crucial contract with the Nevada Department of Health and Human Services.  This will be a five-year contract with a possible two-year extension starting from Jan. 1, 2026 and mark a significant expansion of Medicaid managed care to the state’s rural and frontier areas, regions that had historically been covered under the fee-for-service system.This contract strengthens Centene’s position in the government-sponsored healthcare market. Silversummit has been serving Nevada’s Medicaid population since 2017 and currently supports more than 100,000 members. It is now set to provide integrated healthcare services to an even wider range of people, which will include primary care, behavioral health, pharmacy services and telehealth. These are the key elements that are crucial for enhancing health outcomes in underserved areas.The expansion will establish SilverSummit as a key player in the state’s healthcare scene, focusing on tailored solutions and a broader network of providers. As rural healthcare access is a significant challenge across the country, this initiative might become a blueprint for other states to follow.Moreover, SilverSummit’s marketplace arm, Ambetter, was among the few selected for Nevada’s Battle Born State Plan, a new public option within the health insurance marketplace that offers a mobile app for managing healthcare benefits. This contract is expected to provide coverage for around 16,000 individuals in its inaugural year.This initiative also aligns with Centene’s mission to deliver person-centered care. The Nevada Medicaid contract not only strengthens SilverSummit Healthplan’s role in the community but also highlights a significant trend in the industry toward value-based, community-centered healthcare.CNC Stock Price PerformanceYear to date, CNC  shares have risen 3%, underperforming the industry’s surge of 16.9%. Image Source: Zacks Investment ResearchCNC’s Zacks Rank & Key PicksCNC currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the broader medical space are Aveanna Healthcare Holdings Inc. AVAH, Universal Health Services, Inc. UHS and Option Care Health, Inc. OPCH, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for Aveanna Healthcare’s current-year earnings of $0.12 per share has witnessed six upward revisions in the past 30 days against none in the opposite direction. Aveanna Healthcare beat earnings estimates in each of the trailing four quarters, with the average surprise being 163.3%. The consensus estimate for current-year revenues is pegged at $2.1 billion, implying 4.6% year-over-year growth.The Zacks Consensus Estimate for Universal Health Services’ current-year earnings of $18.94 per share has witnessed three upward revisions in the past 30 days against no movement in the opposite direction. Universal Health Services beat earnings estimates in three of the trailing four quarters, with the average surprise being 15.5%. The consensus estimate for current-year revenues is pegged at $17.1 billion, implying 8.1% year-over-year growth.The Zacks Consensus Estimate for Option Care Health’s current-year earnings of $1.68 per share has witnessed six upward revisions in the past 60 days against no movement in the opposite direction. Option Care Health beat earnings estimates in each of the trailing four quarters, with the average surprise being 15.9%. The consensus estimate for current-year revenues is pegged at $5.4 billion, calling for 8.9% year-over-year growth.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Universal Health Services, Inc. (UHS): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report Option Care Health, Inc. (OPCH): Free Stock Analysis Report Aveanna Healthcare Holdings Inc. (AVAH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Centene und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Centene

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Centene

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Centene Corp.

Wer­bung

Analysen zu Centene Corp.

DatumRatingAnalyst
20.10.2017Centene OutperformBMO Capital Markets
05.04.2017Centene BuyDeutsche Bank AG
08.02.2017Centene OverweightBarclays Capital
07.02.2017Centene OverweightCantor Fitzgerald
20.06.2016Centene OverweightBarclays Capital
DatumRatingAnalyst
20.10.2017Centene OutperformBMO Capital Markets
05.04.2017Centene BuyDeutsche Bank AG
08.02.2017Centene OverweightBarclays Capital
07.02.2017Centene OverweightCantor Fitzgerald
20.06.2016Centene OverweightBarclays Capital
DatumRatingAnalyst
15.06.2015Centene HoldDeutsche Bank AG
15.06.2015Centene Mkt PerformFBR Capital
28.04.2015Centene Mkt PerformFBR Capital
11.02.2015Centene NeutralUBS AG
15.12.2014Centene HoldDeutsche Bank AG
DatumRatingAnalyst
05.12.2006Update Centene Corp.: SellGoldman Sachs
12.06.2006Update Centene Corp.: SellMatrix Research

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Centene Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen